bi-4scar gd2/cd70 t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2022 (NCT05438368)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- CD70 antigenImmunity, passive
CD70 immunity, passive
- Disialoganglioside GD2Immunity, passive
Disialoganglioside GD2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05437341 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2022 | Shenzhen Geno-Immune Medical Institute |
| NCT05438368 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2022 | Shenzhen Geno-Immune Medical Institute |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shenzhen Geno-Immune Medical Institute | Academic/Hospital | 2 | 2 | 1 | 2022 |
1 organizations
Page 1 / 1